Two bootstrapped IT services empires built by Eastern European immigrants who chose different paths to the same ambition: bridging technology and enterprise transformation.
| Dimension | Dmitry Sidney (CT) | Max Votek (CT) | Slava Kreynin (Forte) |
|---|---|---|---|
| Current Title | CEO & Co-Founder | Managing Partner & Co-Founder | Founder, President & Executive Chairman |
| Education | M.S. Computer Science, Taras Shevchenko Natl Univ of Kyiv | Master's, I.M. Sechenov First Moscow State Medical University | B.S. Mathematics & Computer Science, Loyola University Chicago |
| Academic Discipline | Computer Science | Medicine / Pharmacy | Math + CS |
| Pre-Founder Career | SAP CRM Architect (Vodafone Ukraine); Program Manager (Siemens) | Pharmacist; Sales Force Effectiveness Manager (Solvay Pharmaceuticals, ~10 yrs) | Entered entrepreneurship directly after university |
| Founded Company | 2006 (age ~28) | 2006 (age ~28) | 2000 (age ~25) |
| Years as Founder/CEO | 20 years (still CEO) | 20 years (still Managing Partner) | 25 years (CEO 22 yrs; Chairman 3 yrs) |
| Still Runs Day-to-Day? | Yes — CEO | Yes — Managing Partner | No — Hired CEO in 2022 |
| Origin Country | Ukraine | Russia (trained) / Ukraine connection | Immigrant to US (Eastern European roots) |
| Current Base | New York / Boca Raton, FL | Boca Raton, FL | Chicago, IL |
| Other Ventures | None known (single-company focus) | None known (single-company focus) | Peeranha/Peera (Web3, Techstars '22); Leomed (healthcare tech) |
| CEO Approval Rating | N/A (not separately tracked) | N/A | 88/100 Comparably (Top 5%) |
| Public Profile Intensity | Low-Medium — Limited public presence | Medium-High — Podcasts, media quotes, conferences | Medium-High — Conferences, LinkedIn, Ukraine advocacy |
| Defining Quote | Grew CT to ISG Leader alongside companies 200–500x its size | "Americans are quickly waking up to the potential of AI to transform healthcare" | "Bridging the gap between people and technology has always been our passion" |
Two founders, converging at the same destination from different starting points.
| Leadership Trait | CT Founders (Sidney + Votek) | Kreynin (Forte) | Contrast |
|---|---|---|---|
| Founder Archetype | Technical Architect + Domain Expert | People-First Builder | Complementary |
| Primary Superpower | Product vision. Built 10+ proprietary products that create IP-driven moats and accelerators | Culture architecture. Built a 25-year culture so strong he could step back and it sustained itself | Both rare |
| Growth Philosophy | Platform leverage. Bet on Salesforce ecosystem early (2008) and rode the wave. Products amplify consulting. | Organic patience. 25 years of bootstrapped compounding. No shortcuts, no hype cycles. Steady build. | CT faster to market |
| Risk Appetite | Moderate. Multi-platform diversification (SF + MSFT + SAP) hedges bets but concentrates on Salesforce | Adventurous. Launched Web3 startup (Peeranha) and healthcare venture (Leomed) while running Forte | Kreynin bolder |
| Succession Planning | Not yet. Sidney has been CEO for 20 years with no announced succession plan | Completed. Hired Carlsson as CEO in 2022 with a structured transition. Stays as Chairman. | Forte ahead |
| Public Presence | Sidney: Low. Votek: Medium-High (podcasts, media quotes, healthcare AI thought leadership) | Medium-High. Active LinkedIn, conference speaker, Ukraine advocacy, community boards | Kreynin broader |
| Delegation Model | Multi-founder. Sidney (tech + strategy) + Votek (pharma + GTM) + Goldfinger (enterprise sales). Distributed leadership. | Solo-to-professional. Built alone for 22 years, then hired a professional CEO to scale. Currently parallel-paths with own ventures. | CT more distributed |
| Community Impact | Pledge 1% participant; Give Back to Ukraine Fund ($400K+); autism awareness | #StandWithUkraine advocate; Ukraine Recovery Conference speaker; A Red Orchid Theatre board (2011–13) | Both committed |
| Employee Perception | Glassdoor: 4.3/5 (371 reviews); 85% recommend; culture praised | Comparably: 88/100 CEO (Top 5%); A+ leadership; Glassdoor 4.1/5 | Both strong |
Sidney and Votek represent a classic complementary co-founder pairing: the architect and the evangelist. Sidney builds the machine; Votek tells the story in pharma boardrooms. This division of labor is why CT has both deep product IP (Sidney's vision) and deep pharma relationships (Votek's domain credibility).
The risk: Sidney is invisible. In a market that rewards CEO narratives, CT's technical leader has almost no public profile. If enterprise buyers google the CEO, they find very little. Votek partially compensates, but only in the HLS vertical.
Kreynin is a rare long-horizon solo founder who built a $100M+ company over 25 years without outside capital, then had the self-awareness to step back and hire a professional CEO. This combination of founder grit + mature delegation is exceptionally uncommon in mid-market services firms.
The risk: Culture depends on the founder's DNA. Forte's 90% retention and 74.5 NPS were built by Kreynin over two decades. Carlsson is 3.5 years in. The cultural half-life of a founder's influence is typically 5–7 years. The clock is ticking.
■ CT Founders (Sidney + Votek) ■ Kreynin
Dimensions where CT founders lead
Dimensions where Kreynin leads
Dimensions that are too close to call
Builds systems. Built a 1,200-person company and 10+ products with almost zero public profile. The engineering-first founder who lets code and ISG rankings speak. Risk: the market may never hear CT's story.
Translates pharma into technology. A pharmacist who became a tech co-founder — the rarest founder profile in IT services. His domain credibility is why Pfizer and AbbVie are CT clients. Votek is CT's secret weapon.
25 years, no outside money, no shortcuts. Built a culture so strong he could walk away from the CEO seat and it held. Now building parallel ventures (Web3, healthcare) while the mothership runs. The rarest breed: a founder who knows when to let go.
| Decisive Dimension | CT Founders | Kreynin | Verdict |
|---|---|---|---|
| Created lasting IP? | Yes — 10+ products on AppExchange & MS Marketplace | No — Pure services, no product IP | CT |
| Built transferable culture? | Untested — No CEO transition attempted | Yes — 90% retention held through CEO change | Forte |
| Earned independent validation? | ISG Leader 3x alongside $50B+ firms | Inc. 5000 + Clutch 1000 but no analyst coverage | CT |
| Prepared the company for what's next? | Partially — Strong position but no succession plan for 20-year CEO | Yes — CEO hired, AI pivot, LatAm expansion, founder free to explore | Forte |
| Built a business that survives them? | Probably — Product IP has value independent of founders; but no succession test | Tested — 3.5 years of post-CEO-transition performance | Forte (tested) |
Sidney + Votek built something with lasting structural value. The combination of a technical architect who creates products and a pharma-domain expert who opens boardroom doors is a co-founder pairing that competitors cannot replicate. CT's product IP will retain value regardless of who runs the company — but that succession test has never been run.
Founder grade: A-
Deduction for lack of succession planning and Sidney's invisible public profile.
Kreynin built something that endures without him. 25 years of bootstrapped growth, a culture rated in the top 5% of all companies, 90% client retention — and then the hardest thing a founder can do: hand over the keys and walk into the next room. The company held. That's the ultimate founder test.
Founder grade: A
Deduction for leaving no product IP behind and zero analyst coverage during his CEO tenure.
The CT founders built an asset — proprietary products, ISG validation, and blue-chip pharma relationships that have standalone value.
Kreynin built an organism — a self-sustaining culture with 90% retention that survived the ultimate stress test of a founder stepping back.
Assets appreciate. Organisms adapt. In a market being reshaped by AI, consolidation, and platform shifts, both forms of founder legacy will be tested. The founders who win the next decade are the ones who combine both: build products that create value and cultures that sustain it.
Neither founding team has achieved that combination yet. That's the opportunity.